Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
This research study is a multicentre phase Ⅰb/Ⅱ Study to evaluate the efficacy and safety of SHR-A1921 in combination with other anti-cancer agents in patients with advanced solid tumors
Advanced Solid Tumor
DRUG: SHR-A1921；
Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) over the DLT period. （Phase 1b）, up to 21 days of cycle 1|Determination of Recommended Phase II dose (RP2D) （Phase 1b）, Up to 21 days of cycle 1|Objective Response Rate as Assessed by the Investigator according to RECIST v1.1（Phase II）, From baseline to progressive disease or death (approximately 1 year)
Objective Response Rate as Assessed by the Investigator according to RECIST v1.1e (Ph1b only),, From baseline to progressive disease or death (approximately 1 year)]|Duration of Response as Assessed by the Investigator according to RECIST v1.1, From baseline to progressive disease or death (approximately 1 year)|Disease Control Rate as Assessed by the Investigator according to RECIST v1.1, From baseline to progressive disease or death (approximately 1 year)|Time to Response as Assessed by the Investigator according to RECIST v1.1, From baseline to progressive disease or death (approximately 1 year)|Progression-free Survival as Assessed by the Investigator according to RECIST v1.1, From baseline to progressive disease or death (approximately 1 year)|Overall survival, approximately 12months after last patient enrolled.
This research study is a multicentre phase Ⅰb/Ⅱ Study to evaluate the efficacy and safety of SHR-A1921 in combination with other anti-cancer agents in patients with advanced solid tumors